Klarsen

ALKLA

FR0011038348

IT Services & Consulting

Real-time Euronext Paris Other stock markets 03:41:28 2024-04-30 am EDT			5-day change	1st Jan Change
2.65 ^EUR	-5.36%		-10.92%	-2.57%

Mar. 15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
2023	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT

Klarsen : ALKLA-KLARSEN-Eligibilité PEA-PME

March 27, 2023 at 11:58 am EDT

ALKLA-KLARSEN-Eligibilité PEA-PME

27 Mar 2023 17:45 CEST

Issuer

KLARSEN

alkla-communique-du-27-mars-2023-eligibilite-pea-pme0.pdf

Source

KLARSEN

Provider

Euronext

Company Name

KLARSEN

ISIN

FR0011038348

Symbol

ALKLA

Market

Euronext Growth

Attachments

Original Link
Original Document
Permalink

Disclaimer

Klarsen SA published this content on 27 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 March 2023 15:57:31 UTC.

Latest news about Klarsen

Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	Mar. 15	MT
Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	Nov. 07	MT
Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-27	CI
Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	23-03-09	MT
Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	22-12-23	MT
Twitter to shut down newsletter product Revue next year	22-12-14	RE
Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	22-12-05	MT
Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-05	CI
Acticor Biotech's Drug Candidate For Stroke Treatment Receives Europe's Priority Medicines Tag	22-07-22	MT
Klarsen Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Acticor Biotech's Stroke Drug Cuts Risk Of Brain Bleeding, Death In Early-Stage Study	22-02-22	MT
Acticor Biotech COVID-19 Drug Shown Safe But Not More Effective Than Placebo in Study	22-02-02	MT
Acticor Biotech Secures US FDA Clearance to Start Trial of Stroke Treatment	21-11-05	MT
Global markets live: Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resources....	21-06-22
Actiplay : Twitter acquires newsletter startup Revue	21-01-26	RE
Actiplay : Twitter acquires newsletter startup Revue	21-01-26	RE
An unknown buyer acquired minority stake in Groupe Actiplay SA from iXO Private Equity.	20-09-03	CI
Groupe Concoursmania acquired Slix Media.	15-09-02	CI
Groupe Concoursmania completed the acquisition of three games websites from Mastodonte Interactive Inc.	15-03-17	CI
Groupe Concoursmania signed a exclusive agreement in principle to acquire three games websites from Mastodonte Interactive Inc.	15-01-20	CI
Groupe Actiplay SA acquired Telaxo.	12-11-13	CI
Groupe Concoursmania Reports Consolidated Audited Earnings Results for the Year Ended December 31, 2011	12-04-09	CI

Chart Klarsen

Duration

Period

More charts

Company Profile

Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Sector

IT Services & Consulting

More about the company

Income Statement Evolution

More financial data

Sector Other IT Services & Consulting

	1st Jan change	Capi.
KLARSEN	-2.57%	9.94M
ACCENTURE PLC	-13.61%	191B
TATA CONSULTANCY SERVICES LTD.	+1.80%	168B
IBM	+2.37%	153B
AUTOMATIC DATA PROCESSING, INC.	+4.71%	100B
RELX PLC	+6.01%	77.3B
CROWDSTRIKE HOLDINGS, INC.	+19.08%	73.54B
INFOSYS LIMITED	-7.25%	71.18B
SNOWFLAKE INC.	-20.88%	52.58B
HCL TECHNOLOGIES LIMITED	-6.28%	45.02B